DB22674ExperimentalSmall molecule
BHV-1310 is a IgG1,2,4 selective degrader being investigated for the treatment of Grave's disease.
- Mechanism
- Curator reviewed · 1 reference
BHV-1310 selectively targets IgG1, IgG2, and IgG4. It is a bifunctional molecule that binds to IgG autoantibodies, then delivers the complex to asialoglycoprotein receptors on hepatocytes for internalization and lysosomal degradation.
- Code names
- BHV-1310
Resolves to
What you can answer from here — as of July 26, 2025
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with BHV-1310, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account